- Home
- RARE vs RLX Comparison
RARE vs RLX Comparison
Compare RARE & RLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RARE
- RLX
- Stock Information
- Founded
- RARE 2010
- RLX 2018
- Country
- RARE United States
- RLX China
- Employees
- RARE N/A
- RLX N/A
- Industry
- RARE Biotechnology: Pharmaceutical Preparations
- RLX Medicinal Chemicals and Botanical Products
- Sector
- RARE Health Care
- RLX Health Care
- Exchange
- RARE Nasdaq
- RLX Nasdaq
- Market Cap
- RARE 4.2B
- RLX 3.7B
- IPO Year
- RARE 2014
- RLX 2021
- Fundamental
- Price
- RARE $42.59
- RLX $2.43
- Analyst Decision
- RARE Strong Buy
- RLX Strong Buy
- Analyst Count
- RARE 15
- RLX 1
- Target Price
- RARE $93.13
- RLX $2.76
- AVG Volume (30 Days)
- RARE 656.5K
- RLX 4.8M
- Earning Date
- RARE 02-13-2025
- RLX 03-14-2025
- Dividend Yield
- RARE N/A
- RLX 0.33%
- EPS Growth
- RARE N/A
- RLX 607.62
- EPS
- RARE N/A
- RLX 0.07
- Revenue
- RARE $560,230,000.00
- RLX $307,798,132.00
- Revenue This Year
- RARE $19.26
- RLX $117.52
- Revenue Next Year
- RARE $36.92
- RLX $42.76
- P/E Ratio
- RARE N/A
- RLX $34.45
- Revenue Growth
- RARE 29.01
- RLX 99.79
- 52 Week Low
- RARE $37.02
- RLX $1.50
- 52 Week High
- RARE $60.37
- RLX $2.69
- Technical
- Relative Strength Index (RSI)
- RARE 44.76
- RLX 63.09
- Support Level
- RARE $41.73
- RLX $2.29
- Resistance Level
- RARE $44.98
- RLX $2.45
- Average True Range (ATR)
- RARE 1.72
- RLX 0.12
- MACD
- RARE -0.04
- RLX -0.00
- Stochastic Oscillator
- RARE 18.03
- RLX 50.00
About RARE Ultragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi, and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII.
About RLX RLX Technology Inc. each representing the right to receive one (1) ordinary share
RLX Technology Inc is engaged in the manufacturing of e-vapor products for adult smokers. It has an integrated offline distribution and "Branded store plus" retail model tailored to China's e-vapor market.